Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories
- 1 January 2002
- journal article
- Published by Springer Science and Business Media LLC in Neurotoxicity Research
- Vol. 4 (4), 297-313
- https://doi.org/10.1080/10298420290023963
Abstract
Depressive symptomatology is expressed across a wide spectrum of psychiatric disorders including major depression and schizophrenia. Further, depressive symptomatology is also observed in individuals undergoing withdrawal from chronic exposure to various drugs of abuse including cocaine, amphetamine and nicotine. The negative affective state associated with drug withdrawal is phenomenonologically similar to that observed in depressed and schizophrenia patients suggesting that common underlying pathophysiological deficits may be involved in the depressive symptomatology seen across these different psychiatric disorders. The aim of the present review is to examine clinical and preclinical evidence in support of common neurobiological substrates mediating the negative affect associated with different psychiatric illnesses. First, clinical and epidemiological data are presented demonstrating the high comorbidity between nicotine and psychostimulant dependence, and depression or schizophrenia. It is hypothesized that drug use may represent an attempt to self-medicate an underlying negative affective state present in depressed and schizophrenia patients. Second, preclinical findings are presented that demonstrate common neurochemical deficits in drug withdrawal and depression. Taken together, these clinical and preclinical data support the hypothesis that common neurobiological substrates may mediate the depressive state observed across psychiatric diagnostic categories. Therefore, it is proposed that the study of drug-induced depressions in laboratory animals may have heuristic value in identifying the mechanisms underlying the depressive symptomatology associated not only with drug withdrawal but also major depression and schizophrenia.Keywords
This publication has 142 references indexed in Scilit:
- Pharmacotherapy of Schizophrenia Patients With Comorbid Substance AbuseSchizophrenia Bulletin, 1997
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995
- Nicotine dependence and motives for smoking in depressionJournal of Substance Abuse, 1994
- Current advances and trends in the treatment of depressionTrends in Pharmacological Sciences, 1994
- Effects of repeated amphetamine injections on lateral hypothalamic brain stimulation reward and subsequent locomotionBehavioural Brain Research, 1993
- Amphetamine withdrawal: A behavioral evaluationLife Sciences, 1986
- Nicotine as a reinforcer in human subjects and laboratory animalsPharmacology Biochemistry and Behavior, 1983
- Partial improvement in negative schizophrenic symptoms after amphetaminePsychopharmacology, 1982
- Amphetamine withdrawal: Effects on threshold of intracranial reinforcementPsychopharmacology, 1981
- Enhanced lateral hypothalamic self-stimulation responding after chronic exposure to amphetamineBehavioral and Neural Biology, 1980